Allen Capital Group LLC Purchases New Position in Organon & Co. (NYSE:OGN)

Allen Capital Group LLC acquired a new position in shares of Organon & Co. (NYSE:OGN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,057 shares of the company’s stock, valued at approximately $150,000.

Other institutional investors also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. acquired a new stake in Organon & Co. during the 4th quarter worth approximately $2,263,000. Wealth Effects LLC lifted its holdings in shares of Organon & Co. by 13.9% during the fourth quarter. Wealth Effects LLC now owns 58,578 shares of the company’s stock worth $874,000 after buying an additional 7,160 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after acquiring an additional 11,140,388 shares during the period. KBC Group NV raised its stake in Organon & Co. by 66.6% in the 4th quarter. KBC Group NV now owns 12,899 shares of the company’s stock worth $192,000 after purchasing an additional 5,155 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Organon & Co. by 107.6% in the 4th quarter. Blue Trust Inc. now owns 7,599 shares of the company’s stock valued at $113,000 after purchasing an additional 3,938 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 1.3 %

Shares of Organon & Co. stock opened at $15.85 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of 3.14, a PEG ratio of 0.87 and a beta of 0.76. The firm’s 50-day moving average price is $15.44 and its two-hundred day moving average price is $17.98.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the prior year, the business posted $0.78 EPS. The business’s revenue was up 4.1% on a year-over-year basis. On average, analysts forecast that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Organon & Co. presently has a consensus rating of “Hold” and a consensus target price of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.